Health influencers and scientists have both gone crazy for peptides.
The peptide health craze stems from a lot of online hype — centered on gray-market compounds that haven't been rigorously tested in humans and aren't regulated for safety or purity. But among scientists, there is a genuine "revolution" underway — spurred by technological developments revealing an order of magnitude more peptides in our bodies than we ever realized, and by the unexpected and unparalleled success of GLP-1 drugs like Ozempic.
To learn more about what’s driving this excitement – and how much of the peptide hype is really worth your attention – we spoke with Stanford biochemist Jonathan Long, an associate professor of pathology at Stanford Medicine, an affiliate of the Wu Tsai Neurosciences Institute, and an Institute Scholar of Stanford Sarafan ChEM-H.
Editor's Note: After we went to press, Colorado biotech Enveda announced promising but early Phase 1 safety results for ENV-308, an oral drug engineered to mimic Lac-Phe — the "exercise in a pill" molecule Long's lab first characterized in 2022. The trial didn't test actual weight-loss or fitness effects, so the real thing isn't here yet — but Long, a scientific advisor to Enveda, calls it "an extremely exciting potential scientific breakthrough." Read more
Learn more
Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience.
We want to hear from your neurons! Email us at at neuronspodcast@stanford.edu
Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.